Lawmakers blast pharma for ‘outrageous’ prices and ‘anticompetitive conduct’ in culmination of 3-year probe
For years, drugmakers have targeted "weaknesses" in the U.S. healthcare system to reap dividends on older meds, The House Oversight Committee said Friday.
The "outra...